Stem Cell Manufacturing Market Report 2025

The stem cell manufacturing market size has grown strongly in recent years. It will grow from $17.5 billion in 2024 to $19.22 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to advancements in biotechnology, research and development initiatives, clinical trials and therapeutic applications, regulatory framework establishment, investment in infrastructure.

The stem cell manufacturing market size is expected to see rapid growth in the next few years. It will grow to $30.27 billion in 2029 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to increased funding and investments, growing therapeutic applications, emergence of cell-based therapies, rise in clinical trials and approvals, customized and patient-specific therapies. Major trends in the forecast period include focus on 3d bioprinting, expansion in induced pluripotent stem cells (ipscs), automation and robotics integration, standardization and scalability, bioreactor technology advancements.

The increasing geriatric population is anticipated to drive the growth of the stem cell manufacturing market. The geriatric population refers to individuals aged 65 and older, who often experience various health issues due to reduced immunity and the effects of aging. This demographic faces a higher risk of chronic diseases, and stem cell manufacturing can play a crucial role in combating these ailments. For example, in January 2024, the Population Reference Bureau, a nonprofit organization based in Kenya, reported that the number of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Additionally, this age group is expected to grow its share of the total population from 17% to 23% during the same timeframe. Therefore, the expanding geriatric population is a significant driver of the stem cell manufacturing market's growth.

The expanding biotechnology industry is projected to drive the growth of the stem cell manufacturing market in the future. Biotechnology is a broad and rapidly evolving field that includes a variety of products and services utilizing living organisms or their components to create new technologies and solutions. Stem cell manufacturing represents a quickly advancing sector with the potential to transform the biotechnology landscape by developing innovative therapies and treatments for various diseases. For instance, in June 2024, the BioIndustry Association (BIA), a UK-based national trade association for the life sciences and biotechnology sector, reported that biotech companies in the UK secured £622 million in venture capital during the second quarter of 2024, marking an impressive 259% increase from the previous quarter and a 48% rise compared to the same period last year. Thus, the growth of the biotechnology industry is fueling the expansion of the stem cell manufacturing market.

Technological advancement is a significant trend within the stem cell manufacturing market. Various stakeholders are concentrating on utilizing advanced technologies to remain competitive in the industry. For example, in August 2022, Bluebird Bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved ZYNTEGLO. This groundbreaking one-time gene therapy is now authorized for treating beta-thalassemia in patients requiring regular red blood cell transfusions. A key feature of this therapy is its ex-vivo method, where a modified beta-globin gene is integrated into the patient's own hematopoietic stem cells, allowing them to produce normal levels of hemoglobin. This innovative treatment aims to achieve transfusion independence, significantly reducing the treatment burden for individuals with beta-thalassemia. The approval of ZYNTEGLO marks a pivotal milestone in gene therapy, potentially providing a cure and improving the quality of life for those affected.

Major companies within the stem cell manufacturing market are actively pursuing the development of innovative products, with a focus on GM-grade protein to attain a competitive advantage. GM-grade protein is a designation indicating that protein powders and related products meet specific standards for quality and safety. A noteworthy example is ACROBiosystems Inc., a US-based provider of recombinant proteins and critical reagents, which, in November 2023, introduced GM-grade DLL4 protein. This recombinant, soluble form of Delta-such as Ligand 4 (DLL4), a crucial signaling molecule in stem cell development and differentiation, signifies a significant milestone for advancing stem cell-based therapies. The availability of GMP-grade DLL4 ensures a high-quality, consistent, and scalable source of this essential protein, known for promoting the self-renewal and expansion of hematopoietic stem cells (HSCs). Its utilization in stem cell cultures enhances the growth and differentiation of HSCs, contributing to advancements in stem cell research and therapies.

In July 2022, Bio-Techne Corporation, a US-based life sciences company, acquired Namocell Inc. for an undisclosed sum. This strategic acquisition enhances Bio-Techne's capabilities in stem cell research and manufacturing by integrating Namocell's innovative platforms, which are crucial for cell and gene therapy development, cell engineering, and single-cell genomics. Namocell Inc. specializes in high-performance systems for single-cell sorting and dispensing.

Major companies operating in the stem cell manufacturing market include Thermo Fisher Scientific Inc., Merck Millipore, Stemcell Technologies, Fujifilm Holdings Corporation, Takara Bio Group, Lonza Group AG, Sartorius AG, Bio-Rad Laboratories, Becton Dickinson and Company, Bio-Techne Corporation, Miltenyi Biotec, Terumo BCT Inc., Corning Inc., Eppendorf AG, ViaCyte Inc., Merck KGaA, Danaher Corporation, Vericel Corporation, American Cryostem Corporation, Cellgenix GMBH, Aspen Neuroscience Inc., Magenta Therapeutics Inc, Pluristem Therapeutics Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., 3D Biomatrix Inc., Worthington Biochemical Corporation, Bico Group.

North America was the largest region in the stem cell manufacturing market in 2024. Europe was the second-largest region in the stem cell manufacturing market. The regions covered in the stem cell manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Stem cell manufacturing involves the technologies required to transition stem cell tissue culture from laboratory settings to clinical applications, ensuring controlled, reproducible, automated, validated, and safe production for therapeutic purposes.

The primary products within stem cell manufacturing comprise consumables, instruments, and stem cell lines. Consumables are utilized in growing new cells within culture media, contributing to applications in drug development, tissue culture, gene therapy, and toxicity testing. These consumables serve diverse purposes across research, clinical applications, and cell and tissue banking. They are used by a range of end-users including pharmaceutical and biotechnology companies, academic institutes, research laboratories, contract research organizations, hospitals and surgical centers, as well as cell and tissue banks.

The stem cell manufacturing market research report is one of a series of new reports that provides stem cell manufacturing market statistics, including stem cell manufacturing industry global market size, regional shares, competitors with a stem cell manufacturing market share, detailed stem cell manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell manufacturing industry. This stem cell manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stem cell manufacturing market consists of sales of adult stem cells (ASCs), human embryonic stem cells (HESCs), induced pluripotent stem cells (iPSCs), and very small embryonic-such as cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.